- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alkermes Plc (ALKS)
The Alkermes Plc share price today is 50.50, view NASDAQ ALKS stock exchange data. Track the latest Alkermes Plc share price with real-time updates on ALKS stock performance including market cap, day range, 52-week range and dividend yield. Access ALKS charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
49.33
52.51
52 wk Range
25.17
55.67
ALKS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
49.3352.51
52 wk Range
25.1755.67
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALKS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
55.35
Upside
+9.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
14 Buy
3 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 55.35
(+9.61% Upside)
Alkermes Plc SWOT Analysis
Neuro-Innovation Surge | Alkermes' transformation into a high-growth neuro-innovator is reshaping its market position, driven by a robust product portfolio and promising pipeline |
Financial Resilience | Strong Q2 results and a solid cash position of $962.5 million provide Alkermes with flexibility for R&D investments and shareholder value creation |
LYBALVI's Momentum | Explore how LYBALVI's 52% year-over-year sales growth and increased prescriber breadth are bolstering Alkermes' commercial success in the CNS market |
Pipeline Potential | Delve into ALKS 2680's promising results in narcolepsy trials and its potential to position Alkermes as a leader in sleep disorder treatments |
Alkermes Plc Earnings Call Summary for Q2/2026
- Alkermes beat Q2 estimates with revenue of $496M (+8% vs. forecast) and adjusted EPS of $0.00, but shares fell 4.46% on rising costs.
- Proprietary product sales surged 34% YoY to $411.7M, driven by LUMRYZ ($96.6M) following Avadel acquisition integration.
- Company widened full-year GAAP net loss guidance to $95M-$115M due to contingent consideration charges from Avadel deal.
- Q3 revenue guided at $450M-$470M; key catalysts include ALKS 7290 ADHD data by Q3-end and LUMRYZ sNDA filing for idiopathic hypersomnia.
- Management emphasized orexin pipeline as long-term growth driver, positioning alixorexton as leading orexin 2 receptor agonist across narcolepsy types.
Last Updated: 28-07-2026, 06:58 pm
Read Full TranscriptEarnings
Latest Release
28-07-2026
EPS / Forecast
-- / -0.02
Revenue / Forecast
496.01M / 458.98M
Compare ALKS to Peers and Sector
Metrics to compare | ALKS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALKSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 128.1x | 12.8x | −0.3x | |
PEG Ratio | −1.58 | 0.20 | 0.00 | |
Price/Book | 4.7x | 2.8x | 2.6x | |
Price / LTM Sales | 5.1x | 2.2x | 3.0x | |
Upside (Analyst Target) | 14.9% | 20.9% | 56.3% | |
Fair Value Upside | Unlock | 17.7% | 9.8% | Unlock |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Alkermes Plc (ALKS) Share Price Today?
The Alkermes Plc share price today is 50.50.
What is the current Alkermes Plc (ALKS) share price and day range?
As of 29-07-2026, the Alkermes Plc share price is 50.50, with a previous close of 50.50. The share price has ranged from 49.33 to 52.51 today, while the 52-week range spans from 25.17 to 55.67.
What Is the Alkermes Plc Market Cap?
As of today, Alkermes Plc market cap is 8.47B.
What Is the Alkermes Plc (ALKS) Share Price Target?
The average 12-month share price target for Alkermes Plc is 55.35, with a high estimate of 72 and a low estimate of 38. 14 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +9.61% Upside potential.
What Is Alkermes Plc's Earnings Per Share (TTM)?
The Alkermes Plc EPS (TTM) is 0.40.
When Is the Next Alkermes Plc Earnings Date?
Alkermes Plc will release its next earnings report on 28-10-2026.
From a Technical Analysis Perspective, Is ALKS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Alkermes Plc?
The stock symbol for Alkermes Plc is "ALKS."
How Many Times Has Alkermes Plc Stock Split?
Alkermes Plc has split 1 times.
How Many Employees Does Alkermes Plc Have?
Alkermes Plc has 2050 employees.
What Is the ALKS After Hours Price?
ALKS's last after hours stock price is 50.62, the stock has changed by 0.12, or 0.24%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.